Finacea Shortage: What Providers and Prescribers Need to Know in 2026

Finacea (azelaic acid 15%) remains a cornerstone topical agent in the management of papulopustular rosacea. While not currently listed on the FDA drug shortage database, providers are increasingly hearing from patients who are unable to fill their prescriptions due to insurance barriers, formulary restrictions, and limited stocking of the foam formulation. This clinical update summarizes the current availability landscape and practical prescribing strategies to minimize access delays for your patients.

FDA Shortage Status in 2026

As of the date of this publication, azelaic acid 15% (both gel and foam formulations) is not listed on the FDA drug shortage database. Generic azelaic acid 15% gel is manufactured by multiple U.S. and international suppliers, which provides meaningful supply chain redundancy. However, providers should be aware that:

The brand-name Finacea foam is less widely distributed and may be unavailable at many retail pharmacies.

The generic foam has received FDA approval but is not yet widely available at retail locations as of early 2026.

Generic azelaic acid 15% gel is widely available at major pharmacy chains (CVS, Walgreens, Walmart, Kroger).

The Primary Access Problem: Insurance and Formulary Barriers

The most significant barrier to patient access for Finacea in 2026 is not a physical supply shortage — it is formulary restrictions. Providers should be aware of the following payer-side challenges:

Prior Authorization Requirements

Many commercial plans and Medicare Part D plans require prior authorization (PA) for azelaic acid. PA requirements vary widely by insurer. Some plans require documentation of rosacea diagnosis; others require proof that the patient has tried and failed an alternative topical agent (most commonly metronidazole) before approving azelaic acid.

Best practice: Submit the PA request at the time you write the prescription. Include the ICD-10 diagnosis code (L71.9 – Rosacea, unspecified; or L71.0 – Perioral dermatitis; L71.8 – Other rosacea) and a brief clinical note supporting medical necessity.

Step Therapy Requirements

Step therapy (also called "fail first" policy) is common for branded Finacea and sometimes for the generic as well, depending on the payer. Plans typically require a trial of topical metronidazole 0.75% or 1% before approving azelaic acid. If your patient has already tried metronidazole, document this explicitly in the PA request.

If step therapy is newly required for a patient who has been on Finacea successfully, the standard response is to document that:

The patient has a documented history of successful use of azelaic acid.

Switching to a step-preferred agent would be clinically disruptive and could cause disease flare.

Request a step therapy exception based on clinical stability on current therapy.

Clinical Efficacy Context for PA Documentation

When documenting medical necessity for azelaic acid over metronidazole, it is clinically defensible to note that head-to-head RCTs have shown azelaic acid 15% gel to be superior to metronidazole 0.75% gel in reducing erythema and inflammatory lesions (P = 0.005 in one head-to-head study). Additionally, a 2025 systematic review and meta-analysis found that azelaic acid has a better overall efficacy profile than metronidazole for papulopustular rosacea.

Prescribing Tips to Improve Patient Access

Prescribe the generic by name: Write "azelaic acid 15% gel, 50g, generic acceptable" rather than just "Finacea." This reduces delays caused by brand-name PA requirements and helps patients avoid high brand-name costs.

Specify gel over foam: Unless there is a specific clinical reason to use the foam, prescribe the gel. The gel has a widely available generic and is more universally stocked.

Submit PA early: Don't wait for the pharmacy to reject the claim. Call in the PA request at the same time you write the prescription.

Provide bridge options: If a PA will take several days to process, advise patients about GoodRx or SingleCare coupons for the generic — $27–$38 for a 50g tube — so they can start therapy without waiting.

Consider combination therapy: In cohort analyses, the combination of metronidazole and azelaic acid is the most commonly used combination regimen in U.S. dermatology practice. If payer restrictions require metronidazole first, this can be framed as a meaningful combination approach.

When to Consider Therapeutic Alternatives

If azelaic acid access is genuinely unavailable for a patient, the most evidence-supported alternatives for papulopustular rosacea are:

Ivermectin 1% cream (Soolantra/generic): Meta-analyses consistently show superior efficacy vs. azelaic acid for papulopustular rosacea; once-daily dosing.

Metronidazole 0.75-1% gel/cream: Well-established first-line agent; widely available; low cost.

Doxycycline 40 mg modified-release (Oracea/generic): Sub-antimicrobial anti-inflammatory dose; appropriate for moderate-to-severe cases or as adjunct to topical therapy.

Help Your Patients Find Their Medication

When patients are having trouble finding Finacea in stock, medfinder for providers is a service that calls pharmacies near your patients to check which ones can fill a prescription. This can save patients hours of calling around and help them get on therapy faster.